-
May 25, 2025 Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
-
May 20, 2025 Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
-
May 9, 2025 Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States
-
Mar 27, 2025 Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico
-
Feb 13, 2025 Apotex announces grant to Healthy Mothers, Healthy Babies Coalition of Broward County to promote maternal health with $242,000 in annual funding
-
Feb 5, 2025 Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
-
Sep 5, 2024 Apotex Corp. is the first generic manufacturer to launch dasatinib tablets in the United States
-
Sep 5, 2024 Apotex Corp. is the first generic manufacturer to launch oxcarbazepine ER tablets in the United States
-
May 15, 2024 Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the United States
-
Feb 16, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Nov 21, 2023 Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States
-
Sep 5, 2023 Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States
-
Apr 26, 2023 Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States
-
Apr 19, 2023 Apotex Receives FDA’s Drug Shortage Assistance Award
-
Mar 1, 2023 Apotex Corp. Issues Voluntary Nationwide Recall of Brimonidine Tartrate Ophthalmic Solution, 0.15% due to cracks that have developed in some of the units caps of the bottles
-
Apr 12, 2022 Apotex Corp. Launches Generic of Abraxane® in the United States
-
Jan 19, 2022 Apotex Corp. Launches First-to-Market Authorized Generic Version of Combigan® Ophthalmic Solution in the United States
-
Dec 7, 2021 Apotex Corp. Announces Approval and Launch of Atropine Sulfate Ophthalmic Solution USP, 1% in the United States
-
Oct 7, 2021 Product Donation Supports Clinical Study to Evaluate FDA-Approved Medications for Mild-to-Moderate COVID-19 in Outpatients
-
Mar 31, 2021 Apotex Corp. Issues Voluntary Nationwide Recall of Guanfacine Extended-Release Tablets 2mg due to trace amounts of Quetiapine Fumarate
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
May 25, 2025
Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 9, 2025
Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States
Weston, Florida (May 09, 2025) – Apotex Corp. today launched IVRA™ (Melphalan) hydrochloride injection 90mg/ml multidose vial ("IVRA"), first ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States.